The declining role of post-treatment neck dissection in human papillomavirus-associated oropharyngeal cancer

Christopher P Daniels,Howard Yu-Hao Liu,Anne Bernard,Christopher Williams,Matthew C Foote,Rahul Ladwa,Margaret McGrath,Benedict James Panizza,Sandro Virgilio Porceddu,Christopher P. Daniels,Howard Yu-hao Liu,Matthew C. Foote
DOI: https://doi.org/10.1016/j.radonc.2020.08.004
IF: 6.901
2020-10-01
Radiotherapy and Oncology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background and purpose</h3><p>Human papillomavirus-associated oropharyngeal cancer (HPV+ OPC) with regional lymph node metastases has a good prognosis following (chemo)radiation therapy (C/RT) but lymph nodes may remain detectable for several months. Delayed [<sup>18</sup>F]-Fluorodeoxyglucose positron emission tomography / computed tomography (PET) can identify patients who may avoid post-treatment neck dissection (PTND). We investigated the rate of PTND in HPV+ OPC treated with C/RT and delayed PET-directed management of the neck.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Materials and Methods</h3><p>This is a retrospective cohort study from a prospectively updated institutional database. Eligible patients were treated between January 2005 and July 2017 with a minimum of 18 months follow up, had node-positive, non-distant metastatic HPV+ OPC and were treated with RT (70Gy/35#/5 per week) with concurrent Cisplatin or Cetuximab, or accelerated RT alone (68Gy/34#/6 per week). The primary endpoint was rate of PTND. Secondary endpoints were locoregional failure free survival (LRFFS), regional failure free survival (RFFS), distant metastatic failure free survival (DMFFS), overall survival (OS) and oropharyngeal cancer-specific survival (CSS).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>418 patients were eligible. Nineteen patients (4.5%) received a PTND. None of the tested variables were associated with an increased risk of PTND. Five-year probabilities for LRFFS, RFFS, DMFS, OS and CSS were, 91.2% (95% CI 88.3 – 94.2), 93.4% (95% CI 90.8 – 96.0), 91.2% (95% CI 88.3 – 94.2), 86.4% (95% CI 83.0 – 90.1) and 90.2% (95% CI 87.1-93.4), respectively.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>In a large cohort with good median follow up and protocolized C/RT, delayed PET-directed management of the neck affords a lower rate of PTND than reported in historical series without compromising disease control and survival.</p>
oncology,radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?